Delivery Order SPE2DB22D1103-SPE2DB25FTGR8

Award Date 3/7/25
Potential Completion Date 3/10/25
Potential Value $3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 1,000 units of 40 mg Lisinopril tablets. The contract has a ceiling value of $4,312.22 and runs through February 27, 2025. It is a firm-fixed-price delivery order contract, with no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The $1,661.04 firm fixed-price delivery order is for the supply of 4564374289 - Lisinopril-HCTZ 20-12.5 mg Tablets, 500 count. The award does not have a set-aside designation. AmerisourceBergen Drug Corp holds a single-award Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA Troop Support Medical through December 31, 2025. This contract...
This federal contract award, valued at $1,212.73, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,563,557,309 units of Lisinopril 40 mg tablets. It is a firm-fixed-price delivery order contract with a completion date of February 6, 2024. There is no set-aside designation for this award. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Lisinopril-HCTZ 20-12.5 mg tablets. The contract has a ceiling value of $2,069.52 and an ultimate completion date of April 25, 2023. The contract is a Delivery Order under the firm fixed price pricing type. It is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of...
This federal contract award is for the delivery of Lisinopril-HCTZ 20-12.5 mg tablets in 1,000 count sizes. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The award is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to support military treatment...
The Defense Logistics Agency awarded a $290,640 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 1,000 tablets of the pharmaceutical lisinopril. As the prime contractor, Amerisourcebergen will deliver the hypertension medication to its Conshohocken, Pennsylvania facility by September 5, 2023 under the terms of the contract. No major subcontractors or set aside designations were indicated. The Defense Logistics Agency routinely issues delivery orders to establish domestic...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,773.34, is a delivery order for the supply of AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a $198.01 firm fixed price delivery order by the Defense Logistics Agency Troop Support Medical to supply 1,000 tablets of the 40mg dosage of the hypertension medication lisinopril. Performance will take place in Conshohocken, Pennsylvania over a one day period from August 30th to August 31st, 2023. The Defense Logistics Agency Troop Support Medical supports the Department of Defense's global supply...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distributor. The $27,021.98 fixed-price delivery order is for the supply of Zestoretic 20-12.5 mg tablets. This delivery order is part of an indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,555.51, is a delivery order for AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a medical commodity. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
  • SPE2DB22D1103
    Indefinite Delivery Contract
  • SPE2DB22D1103-SPE2DB25FTGR8
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,989.87, is a delivery order for Lisinopril 10 mg tablets. The contract does not have a set-aside designation, indicating open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 6/6/25, 9:45 AM